(Q35225256)

7 August 2017

0 references

Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis (English)

1 reference

7 August 2017

1 reference

1 reference

1 reference

Xu-Ping Yang

1

1 reference

7 August 2017

Dan Lai

2

1 reference

7 August 2017

Xiao-Yan Zhong

3

1 reference

7 August 2017

Hong-Ping Shen

4

1 reference

7 August 2017

Yi-Lan Huang

5

1 reference

7 August 2017

publication date

16 August 2014

1 reference

European Journal of Clinical Pharmacology

7 August 2017

published in

1 reference

7 August 2017

volume

70

1 reference

7 August 2017

issue

10

1 reference

7 August 2017

page(s)

1149-1158

1 reference

National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1730-X

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1730-X

Management of type 2 diabetes: new and future developments in treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1730-X

Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1730-X

Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1730-X

Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1730-X

Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1730-X

Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1730-X

The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1730-X

A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1730-X

Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1730-X

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1730-X

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1730-X

Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1730-X

Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1730-X

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1730-X

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1730-X

Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1730-X

Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1730-X

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1730-X

Standards of medical care in diabetes--2013

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1730-X

The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1730-X

Improvement in β-cell function after diet-induced weight loss is associated with decrease in pancreatic polypeptide in subjects with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1730-X

Effect of diuretics on the plasma lipid profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1730-X

Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-014-1730-X

Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects

21 January 2018

1 reference

12 December 2020

Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes

1 reference

12 December 2020

Dapagliflozin, an oral sodium glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus

1 reference

12 December 2020

Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with Type 2 diabetes in UK primary care

1 reference

12 December 2020

Effects of Differing Antecedent Hypoglycemia on Subsequent Counterregulation in Normal Humans

1 reference

12 December 2020

10.1007/S00228-014-1730-X

Identifiers

DOI

1 reference

7 August 2017

1 reference